TS-011 |
カタログ番号GC32657
One-Click Copy Product Info
|
TS-011 は、20-ヒドロキシエイコサテトラエン酸合成の選択的阻害剤です。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 339071-18-0
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
TS-011 is a selective inhibitor of 20-Hydroxyeicosatetraenoic acid synthesis.
TS-011 is a selective inhibitor of 20-Hydroxyeicosatetraenoic acidsynthesis. TS-011 at a dose of 0.3 mg/kg inhibits the reduction in the blood flow velocities at 1 and 7 h after reperfusion (P<0.001). In addition, TS-011 inhibits the increase in the blood flow velocity at 24 h after reperfusion (P<0.01). TS-011 protects the microvascular perfusion area from the loss observed in vehicle-treated mice. TS-011, at a dose of 0.3 mg/kg, also reduces the infarct volume by almost 40% (P<0.05)[1]. In 9 dogs with delayed vasospasm, acute blockade of the synthesis of 20-HETE with TS-011 (1 mg/kg IV) significantly increases the diameter of the basilar artery by 39%[2].
[1]. Marumo T, et al. The inhibitor of 20-HETE synthesis, TS-011, improves cerebral microcirculatory autoregulation impaired by middle cerebral artery occlusion in mice. Br J Pharmacol. 2010 Nov;161(6):1391-402. [2]. Hacein-Bey L, et al. Reversal of delayed vasospasm by TS-011 in the dual hemorrhage dog model of subarachnoid hemorrhage. AJNR Am J Neuroradiol. 2006 Jun-Jul;27(6):1350-4.
Animal experiment: | The studies are performed using 58 male C57BL/6J mice (8 weeks old) weighing 20 to 26 g. TS-011 (0.3 mg/kg) or a vehicle is infused intravenously for 1 h every 6 h in a mouse model of stroke, induced by transient occlusion of the middle cerebral artery occlusion following photothrombosis. The cerebral blood flow velocity and the vascular perfusion area of the peri-infarct microvessels are measured using in vivo two-photon imaging[1]. |
References: [1]. Marumo T, et al. The inhibitor of 20-HETE synthesis, TS-011, improves cerebral microcirculatory autoregulation impaired by middle cerebral artery occlusion in mice. Br J Pharmacol. 2010 Nov;161(6):1391-402. | |
| Cas No. | 339071-18-0 | SDF | |
| Canonical SMILES | ClC(C=C(/N=C/NO)C=C1)=C1N2CCOCC2 | ||
| Formula | C11H14ClN3O2 | M.Wt | 255.7 |
| 溶解度 | Soluble in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.9108 mL | 19.5542 mL | 39.1083 mL |
| 5 mM | 782.2 μL | 3.9108 mL | 7.8217 mL |
| 10 mM | 391.1 μL | 1.9554 mL | 3.9108 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 20 reference(s) in Google Scholar.)